0000899243-18-008245.txt : 20180321 0000899243-18-008245.hdr.sgml : 20180321 20180321160031 ACCESSION NUMBER: 0000899243-18-008245 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180319 FILED AS OF DATE: 20180321 DATE AS OF CHANGE: 20180321 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Paggiarino Dario A. CENTRAL INDEX KEY: 0001574261 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 18704451 MAIL ADDRESS: STREET 1: 4025 SORRENTO VALLEY BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: pSivida Corp. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-03-19 0 0001314102 pSivida Corp. PSDV 0001574261 Paggiarino Dario A. C/O PSIVIDA CORP. 480 PLEASANT STREET WATERTOWN MA 02472 0 1 0 0 Chief Medical Officer Common stock 2018-03-19 4 A 0 8333 0.00 A 8333 D On March 19, 2018 (the "NDA Acceptance Date"), the U.S. Food and Drug Administration ("FDA") accepted pSivida Corp.'s (the "Company") new drug application for Durasert 3-year treatment for posterior segment uveitis. As a result, 4,166 shares representing a previously granted performance stock unit award vested on that date. An additional 4,167 shares from this award will vest on the first anniversary of the NDA Acceptance Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date. /s/ John Mercer, Attorney-in-Fact 2018-03-21